Literature DB >> 21083380

Mutations in GNA11 in uveal melanoma.

Catherine D Van Raamsdonk1, Klaus G Griewank, Michelle B Crosby, Maria C Garrido, Swapna Vemula, Thomas Wiesner, Anna C Obenauf, Werner Wackernagel, Gary Green, Nancy Bouvier, M Mert Sozen, Gail Baimukanova, Ritu Roy, Adriana Heguy, Igor Dolgalev, Raya Khanin, Klaus Busam, Michael R Speicher, Joan O'Brien, Boris C Bastian.   

Abstract

BACKGROUND: Uveal melanoma is the most common intraocular cancer. There are no effective therapies for metastatic disease. Mutations in GNAQ, the gene encoding an alpha subunit of heterotrimeric G proteins, are found in 40% of uveal melanomas.
METHODS: We sequenced exon 5 of GNAQ and GNA11, a paralogue of GNAQ, in 713 melanocytic neoplasms of different types (186 uveal melanomas, 139 blue nevi, 106 other nevi, and 282 other melanomas). We sequenced exon 4 of GNAQ and GNA11 in 453 of these samples and in all coding exons of GNAQ and GNA11 in 97 uveal melanomas and 45 blue nevi.
RESULTS: We found somatic mutations in exon 5 (affecting Q209) and in exon 4 (affecting R183) in both GNA11 and GNAQ, in a mutually exclusive pattern. Mutations affecting Q209 in GNA11 were present in 7% of blue nevi, 32% of primary uveal melanomas, and 57% of uveal melanoma metastases. In contrast, we observed Q209 mutations in GNAQ in 55% of blue nevi, 45% of uveal melanomas, and 22% of uveal melanoma metastases. Mutations affecting R183 in either GNAQ or GNA11 were less prevalent (2% of blue nevi and 6% of uveal melanomas) than the Q209 mutations. Mutations in GNA11 induced spontaneously metastasizing tumors in a mouse model and activated the mitogen-activated protein kinase pathway.
CONCLUSIONS: Of the uveal melanomas we analyzed, 83% had somatic mutations in GNAQ or GNA11. Constitutive activation of the pathway involving these two genes appears to be a major contributor to the development of uveal melanoma. (Funded by the National Institutes of Health and others.).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21083380      PMCID: PMC3107972          DOI: 10.1056/NEJMoa1000584

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  35 in total

1.  Pasteurella multocida toxin activation of heterotrimeric G proteins by deamidation.

Authors:  Joachim H C Orth; Inga Preuss; Ines Fester; Andreas Schlosser; Brenda A Wilson; Klaus Aktories
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-15       Impact factor: 11.205

2.  Ultraviolet-B phototoxicity and hypothetical photomelanomagenesis: intraocular and crystalline lens photoprotection.

Authors:  Martin A Mainster; Patricia L Turner
Journal:  Am J Ophthalmol       Date:  2010-04       Impact factor: 5.258

Review 3.  Uveal melanoma: epidemiologic aspects.

Authors:  Arun D Singh; Louise Bergman; Stefan Seregard
Journal:  Ophthalmol Clin North Am       Date:  2005-03

4.  A comprehensive catalogue of somatic mutations from a human cancer genome.

Authors:  Erin D Pleasance; R Keira Cheetham; Philip J Stephens; David J McBride; Sean J Humphray; Chris D Greenman; Ignacio Varela; Meng-Lay Lin; Gonzalo R Ordóñez; Graham R Bignell; Kai Ye; Julie Alipaz; Markus J Bauer; David Beare; Adam Butler; Richard J Carter; Lina Chen; Anthony J Cox; Sarah Edkins; Paula I Kokko-Gonzales; Niall A Gormley; Russell J Grocock; Christian D Haudenschild; Matthew M Hims; Terena James; Mingming Jia; Zoya Kingsbury; Catherine Leroy; John Marshall; Andrew Menzies; Laura J Mudie; Zemin Ning; Tom Royce; Ole B Schulz-Trieglaff; Anastassia Spiridou; Lucy A Stebbings; Lukasz Szajkowski; Jon Teague; David Williamson; Lynda Chin; Mark T Ross; Peter J Campbell; David R Bentley; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

5.  Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin.

Authors:  Igor Adameyko; Francois Lallemend; Jorge B Aquino; Jorge A Pereira; Piotr Topilko; Thomas Müller; Nicolas Fritz; Anna Beljajeva; Makoto Mochii; Isabel Liste; Dmitry Usoskin; Ueli Suter; Carmen Birchmeier; Patrik Ernfors
Journal:  Cell       Date:  2009-10-16       Impact factor: 41.582

6.  Oncogenic mutations in GNAQ occur early in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Long; Shenghui Duan; M Laurin Council; Anne M Bowcock; J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-21       Impact factor: 4.799

7.  Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.

Authors:  Catherine D Van Raamsdonk; Vladimir Bezrookove; Gary Green; Jürgen Bauer; Lona Gaugler; Joan M O'Brien; Elizabeth M Simpson; Gregory S Barsh; Boris C Bastian
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

8.  Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma.

Authors:  J Bauer; E Kilic; J Vaarwater; B C Bastian; C Garbe; A de Klein
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

9.  Mutational profile of GNAQQ209 in human tumors.

Authors:  Simona Lamba; Lara Felicioni; Fiamma Buttitta; Fonnet E Bleeker; Sara Malatesta; Vincenzo Corbo; Aldo Scarpa; Monica Rodolfo; Margaret Knowles; Milo Frattini; Antonio Marchetti; Alberto Bardelli
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

10.  Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.

Authors:  Heidi V N Küsters-Vandevelde; Annelies Klaasen; Benno Küsters; Patricia J T A Groenen; Ilse A C H van Engen-van Grunsven; Marcory R C F van Dijk; Guido Reifenberger; Pieter Wesseling; Willeke A M Blokx
Journal:  Acta Neuropathol       Date:  2010-03       Impact factor: 17.088

View more
  515 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 3.  New strategies in melanoma: molecular testing in advanced disease.

Authors:  Scott E Woodman; Alexander J Lazar; Kenneth D Aldape; Michael A Davies
Journal:  Clin Cancer Res       Date:  2012-01-24       Impact factor: 12.531

4.  GNAQ and GNA11 mutations in melanocytomas of the central nervous system.

Authors:  Rajmohan Murali; Thomas Wiesner; Marc K Rosenblum; Boris C Bastian
Journal:  Acta Neuropathol       Date:  2012-02-04       Impact factor: 17.088

Review 5.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

6.  Use of Targeted Next-Generation Sequencing to Identify Activating Hot Spot Mutations in Cherry Angiomas.

Authors:  Nikolai Klebanov; William M Lin; Mykyta Artomov; Michael Shaughnessy; Ching-Ni Njauw; Romi Bloom; Agda Karina Eterovic; Ken Chen; Tae-Beom Kim; Sandy S Tsao; Hensin Tsao
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

Review 7.  Genetics of metastasis: melanoma and other cancers.

Authors:  Noel Turner; Olivia Ware; Marcus Bosenberg
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

8.  Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.

Authors:  Stephan W Jahn; Karl Kashofer; Iris Halbwedl; Gerlinde Winter; Laila El-Shabrawi-Caelen; Thomas Mentzel; Gerald Hoefler; Bernadette Liegl-Atzwanger
Journal:  Mod Pathol       Date:  2015-03-13       Impact factor: 7.842

Review 9.  Targeted therapies in melanoma.

Authors:  Stergios J Moschos; Ramya Pinnamaneni
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

Review 10.  [Molecular diagnostics of melanomas].

Authors:  K G Griewank
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.